StockNow
Log in
U.S. Markets

Medtronic (MDT) Q4 2026 (USD): adj. EPS 1.55 (exp. 1.54), Revenue 9.81bln (exp. 9.62bln)

News detail

SEGMENTS: Cardiovascular revenue +13.8% to USD 3.797bln Neuroscience +5.0% to USD 2.751bln Medical Surgical +8.0% to USD 2.388bln  Diabetes +15.0% to USD 837mln Cardiac Ablation Solutions revenue rose 78% globally and 124% in the US GUIDANCE:Next FY EPS view 5.90-6.00 (exp. 6.05)COMMENTARY: Expects approximately USD 250mln in tariff impact to FY27 cost of goods sold, representing a USD 65mln incremental year-on-year increase, and is not assuming any government refund. CEO said Medtronic delivered its strongest annual top-line growth in 10 years and cited momentum in CRM, CST, Surgical, Affera, Symplicity, Hugo, Altaviva and Stealth AXiS.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)